智通财经APP讯,中国抗体-B(03681)发布公告,于2024年11月11日,公司已根据其购股权计划向王善春先生,一名执行董事授出1006.24万份购股权,以供认购合共1006.24万股公司新股份,但须待承授人接纳后方可作实。购股权的行使价为每股1.256港元。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.